![\"\"](\"http:\/\/stateofthenation.co\/wp-content\/uploads\/2021\/05\/6095406c85f540501c5a629a.jpg\")
FILE PHOTO: A man receives an injection with a dose of AstraZeneca coronavirus vaccine, at a vaccination centre in Baitul Futuh Mosque, amid the outbreak of coronavirus disease (COVID-19), in London, Britain, March 28, 2021. \u00a9 REUTERS \/ Henry Nicholls<\/p><\/div><\/p>\n
RT.com<\/p>\n
The European Medicines Agency (EMA) is investigating reports of AstraZeneca\u2019s Covid-19 vaccine causing Guillain-Barre syndrome, as the pharmaceutical company remains embroiled in controversy over the jab\u2019s link to blood clotting.<\/p>\n
In a meeting this week, the European Medicines Agency\u2019s Pharmacovigilance Risk Assessment Committee (PRAC)\u00a0revealed<\/a>\u00a0that it was\u00a0\u201cassessing reports\u201d<\/em>\u00a0of the rare immune system disorder being found in people following vaccination.<\/p>\n \u201cAs part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca\u2019s Covid-19 vaccine, the PRAC is analysing data provided by the marketing authorization holder on cases of Guillain-Barre syndrome (GBS) reported following vaccination\u201d<\/em>, the PRAC declared.<\/p>\n \u201cGBS was identified during the marketing authorization process as a possible adverse event requiring specific safety monitoring activities\u201d<\/em>, the committee continued, adding that it has requested\u00a0\u201cfurther detailed data\u201d<\/em>\u00a0on the cases and will release new information as it becomes available.<\/p>\n